For ALK-rearranged advanced NSCLC, second-generation TKIs, were widely accepted as the front-line standard treatments because of improvement in PFS over crizotinib, impressive central nervous system activity, and favorable toxicity profiles [36–38]. This evidence concerns the gene ALK and non-small cell lung carcinoma.